INBS - ibs.inc Debt to Book Capitalization Ratio

Corporate company logo of Intelligent Bio (INBS)

Intelligent Bio Solutions is diversifying its fingerprint bioanalysis sales across forensics and sports. The total debt-to-capitalization ratio on GURU.Markets illustrates the financial stability trend, where 0.35 reflects the latest value of the metric. The uniqueness of non-invasive tests allows the company to maintain premium pricing, while steady demand for medtech minimizes the impact of macroeconomic cycles.

Intelligent Bio Solutions Inc - INBS Debts to Book Capitalization (period 04/28/2023 - 10/27/2026)
Flagship merchandise of Intelligent Bio Solutions Inc

This ratio determines the extent of the company's reliance on debt relative to its balance sheet equity. Investors utilize this metric to assess financial stability and the acceptable level of debt load. Correlating financial liabilities with book capitalization on the GURU.Markets platform allows users to filter out market noise and identify actual leverage. For Intelligent Bio Solutions (INBS), this balance is critical when scaling the Intelligent Fingerprinting system. An increase in borrowings is permissible only if B2B sales accelerate and regulatory approvals in the US are successfully obtained.

Competitors of Intelligent Bio Solutions

DXCM: Debts to Book Capitalization|penumbrainc.com - Debts to Book Value|Debt to Book Capitalization Ratio Novanta (NOVT)|HAE - Debt to Net Assets Ratio|INSP: Debts to Book Capitalization|PRCT (Procept) - Debts to Book Capitalization|Debt to Book Capitalization Ratio CONMED Corporation CNMD|Debts to Book Capitalization Ratio pulsebiosciences.com|InMode - Debts to Book Capitalization|Debts to Book Value Picard Medical Corp PMI|Debt to Book Value SRDX (Surmodics Corp)|SENS - Debts to Book Capitalization|Debt to Book Value NeuroPace, Inc. NPCE|TCMD - Debt to Book Capital|SANUWAVE - Debts to Book Capitalization|Outset Medical Inc (OM) - Debts to Net Assets|Debts to Book Capitalization ELMD|Debt to Book Value LENSAR Inc (LNSR)|AVITA Medical, Inc. (RCEL) - Debt to Book Value|Debt to Net Assets Ratio PROF (profoundmedical.com)|Baird Medical - Debt to Book Capitalization Ratio|Debt to Book Value EDAP TMS SA EDAP|APYX (Bovie Medical) - Debts to Book Capitalization|ICCM - Debts to Book Value|Debts to Book Capitalization pulmonx.com|TELA Bio (TELA) - Debt to Book Value Ratio|CTSO: Debts to Book Capitalization|Debts to Net Assets Sensus Healthcare Inc|Debts to Book Capitalization ZYXI (Zynex Inc)|Debt to Book Value electrocore.com (ECOR)|Debts to Book Capitalization RBOT (Vicarious Surgical)|Inspira Technologies Oxy B.H.N. Ltd. - Debts to Book Capitalization|ICU - Debt to Book Capitalization Ratio|IRIDEX Corporation (IRIX) - Debt to Book Capitalization Ratio|Debt to Book Value beyondair.net XAIR|Profusa, Inc (PFSA) - Debt to Net Assets Ratio|Debts to Book Capitalization SSKN (STRATA Skin Sciences Inc.)|Debts to Book Value GCTK|NAOV: Debt to Book Capitalization Ratio|Debt to Net Assets Venus Concept Inc VERO|Debt to Book Value NUWE (CHF Solutions)|Debts to Book Capitalization Aethlon Medical Corp AEMD|Debts to Book Capitalization ASXC (TransEnterix)|AVGR: Debts to Net Assets|Debt to Book Capitalization Ratio Biosig Technologies (BSGM)|CUTR (Cutera Inc.) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio KNW|Debt to Book Value Inari Medical Corp|Nevro Corp. - Debts to Book Capitalization|Debts to Book Value RSLS (reshapelifesciences.com)|SILK - Debt to Book Capitalization Ratio